Silver-coated barrier dressing cleared by FDA
This article was originally published in Clinica
Executive Summary
The US FDA has granted 510(k) marketing clearance for Acticoat Flex, an antimicrobial barrier dressing designed to treat injuries that require sustained antimicrobial activity. Acticoat Flex is coated with Silcryst, a nanocrystalline silver technology, and was developed by Nucryst Pharmaceuticals (Princeton, New Jersey) in collaboration with Smith & Nephew. The companies have a partnership to provide advanced antimicrobial protection to acute trauma and burn patients, as well as to patients with complex chronic wounds. Nucryst is also developing the nanocrystalline silver in a powder form, referred to as NPI 32101, for use in medical devices and as a pharmaceutical.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.